Książki

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you're likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You'll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.



Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions.
Covers the best uses for new biologic therapeutics.
Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors.
Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
Features a highly detailed, disease-specific index, as well as purchase information for major drugs.
Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Comprehensive Dermatologic Drug Therapy

Part I: Introduction



1 Basic Principles of Pharmacology



2 Principles for Maximizing the Safety of Dermatologic Drug Therapy



3 Polymorphisms: Why Individual Drug Responses Vary



4 Adherence to Drug Therapy



5 Medical Decision Making



Part II: Important Drug Regulatory Issues



6 The FDA Drug Approval Process



7 Pharmacovigilance: Verifying that Drugs Remain Safe



8 Drugs Taken Off the Market: Important Lessons Learned



Part III: Systemic Drugs for Infectious Diseases



9 Systemic Antibacterial Agents



10 Systemic Antifungal Agents



11 Systemic Antiviral Agents



12 Systemic Antiparasitic Agents



Part IV: Systemic Immunomodulatory Drugs



13 Systemic Corticosteroids



14 Methotrexate



15 Azathioprine



16 Mycophenolates



17 Cyclosporine



18 Phosphodiesterase-4 and Janus Kinase Inhibitors



19 Cytotoxic Agents



20 Dapsone



21 Antimalarial Agents



22 Systemic Retinoids



Part V: Drugs Used in Conjunction with UV or Visible Light



23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities



24 Extracorporeal Photochemotherapy (Photopheresis)



25 Photodynamic Therapy



Part VI: Biologic Therapeutics



26 Tumor Necrosis Factor Inhibitors



27 Interleukin 12/23 Inhibitors



28 Interleukin 17 Inhibitors



29 Interleukin 23 Inhibitors



30 Rituximab



31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others



Part VII: Miscellaneous Systemic Drugs



32 Antihistamines



33 Vasoactive and Antiplatelet Agents



34 Antiandrogens and Androgen Inhibitors



35 Psychotropic Agents



36 Intravenous Immunoglobulin Therapy



37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events



38 Hedgehog Pathway Inhibitors



39 Drugs for the Skinternist



40 Miscellaneous Systemic Drugs



Part VIII: Topical Drugs for Infectious Diseases



41 Topical Antibacterial Agents



42 Topical Antifungal Agents



43 Topical and Intralesional Antiviral Agents



44 Topical Antiparasitic Agents



Part IX: Topical Immunomodulatory Drugs



45 Topical Corticosteroids



46 Topical Retinoids



47 Topical and Intralesional Chemotherapeutic Agents



48 Topical Calcineurin Inhibitors



49 Topical Vitamin D3



Part X: Miscellaneous Topical Drugs



50 Sunscreens



51 Therapeutic Shampoos



52 ?-Hydroxy Acids



53 Chemical Peels



54 Products for the Care of Chronic Wounds



55 Agents Used for Treatment of Hyperkeratosis



56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents



57 Miscellaneous Topical Agents



Part XI: Injectable and Mucosal Routes of Drug Administration



58 Local Anesthetics



59 Injectable Dermal and Subcutaneous Fillers



60 Botulinum Toxin Injections



61 Oral Mucosal Therapeutics



Part XII: Major Adverse Effects From Systemic Drugs



62 Hepatotoxicity of Dermatologic Drug Therapy



63 Hematologic Toxicity of Drug Therapy



64 Drug-induced Malignancy



65 Dermatologic Drugs During Pregnancy and Lactation



66 Drug Interactions



67 Cutaneous Drug Reactions With Systemic Features



Part XIII: Special Pharmacology and Therapeutics Topics



68 Informed Consent and Risk Management



69 Compounding in Dermatology



70 Dermatologic Drug Therapy in Children



Appendix I Core Questions for Understanding Systemic Dermatologic Drugs



Appendix II The Most Potentially Serious Drug Interactions